Proceedings from the Workshop on Biomedical Materials at the Edge Challenges in the Convergence of Technologies (2006) / Chapter Skim
Currently Skimming:
Workshop Summary
Workshop Summary
Pages 1-12
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 2... ...
Scarborough National Research Council INTRODUCTION Rapid developments in biomedical materials are being enabled by continuous advances in other areas of science, such as genomics and proteomics, cell-processing techniques, supramolecular chemistry, permutational chemistry, bioinformatics, and information technology. The need for interdisciplinary research in biomedical materials is therefore increasing, with the most exciting potential for new therapies lying at the point where a number of research disciplines converge.
|
From page 3... ...
. CONTEXT FOR NEW BIOMEDICAL MATERIALS To understand the context in which new biomedical materials are evolving and the challenges and opportunities faced in creating innovative medical therapies from these emerging materials, it is important to understand current policy, regulatory, and economic conditions.
|
From page 4... ...
with the Translating Research into Practice (TRIP-II) Initiative.3 This effort focuses on the techniques and factors associated with successfully translating original research into routine clinical practice.
|
From page 5... ...
The task force submitted a report to the Secretary of HHS in January 2005 outlining opportunities for synergy and collaboration both within and between HHS and other government and private organizations.5 The successful development of an innovative medical technology will depend on economic as well as policy and regulatory conditions. Annabelle Hett explained that an emerging biomedical material may face additional economic hurdles because it is difficult to define the risks associated with it.
|
From page 6... ...
Finally, public perception is an unknown variable in evaluating technology risk. In summary, more accurate terminology, an improved ability to assess risk and severity, and improved regulatory guidelines are needed for insurance companies to develop appropriate models to support new technologies such as nanotechnology.
|
From page 7... ...
6At the time of the workshop, NIH funding was restricted to work using stem cell lines established prior to August 9, 2001. In the November 2004 election, California voters passed a state resolution providing funds to support stem cell research in California.
|
From page 8... ...
Solvents such as cyclohexanes enable the use of phospholipids to create the supramolecular structures. James Harden engineers proteins for specific biomaterials applications using modular protein polymers, much like synthetic block copolymers, for biomimetic designs.
|
From page 9... ...
The biocompatibility of these materials must be better understood, however, as proteins can trigger rejection when recognized as foreign by the immune system. SUPRAMOLECULAR BIOMATERIALS ENGINEERING AND DESIGN The final technical session of the workshop focused on the creation of new biomaterials using nanotechnology -- in other words, supramolecular biomaterials engineering and design.
|
From page 10... ...
Because of the small proportion of nanotechnology funding from venture capitalists, federal funding remains important for the early support and development of this technology. To support and educate the growing nanotechnology business community, the Chicago Microtechnology and Nanotechnology Community trade organization holds public educational seminars and special events.
|
From page 11... ...
In the past, incidental exposures to nanomaterials such as asbestos caused significant harm to public health. There is currently some negative public perception of nanotechnology materials as having potentially adverse environmental and health impacts.
|
From page 12... ...
KEY QUESTIONS The workshop presentations and discussions raised six new and important questions for further consideration: · What is the best business model for developing complex new biomedical materials, such as cell-based therapies? · Is new policy necessary to ensure that the U.S.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.